IR BioSciences Holdings, Inc. (IRBS.OB) Subsidiary Explores Possibility of Partnership with Archimedes Development Ltd

QualityStocks would like to highlight IR BioSciences Holdings, Inc. (OTCBB: IRBS). ImmuneRegen BioSciences Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc., is a development-stage biotechnology company focused on the research, development and licensing of Homspera® and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing.

In the company’s news yesterday,

ImmuneRegen BioSciences, Inc. announced that it has executed a Material Transfer Agreement (MTA) with Archimedes Development Limited. This collaboration enables the companies to identify possible synergies between their technology platforms.

“Multiple studies in different model systems have shown that Homspera can protect experimental animals and enhance their immune responses to vaccine-delivered antigens, DNA-encoded viral proteins or tumor antigens, as well as provide protection in our anthrax and influenza therapeutic studies,” stated Hal Siegel, Ph.D., ImmuneRegen’s Vice President and Chief Scientific Officer.

He continued, “In addition to these findings in animals where Homspera has been administered intranasally as a liquid, inhaled or injected under the skin, we have shown in laboratory studies that Homspera can stimulate blood-forming stem cells to produce more white blood cell precursors, particularly those for granulocytes and macrophages, mature blood cells which play a significant role in immune responses. The ability to administer Homspera intranasally is one we are particularly interested in pursuing. Mucosal vaccination may be more efficacious than injected vaccines for diseases like influenza, intestinal diseases and HIV/AIDS. At times, such as pandemic influenza treatment or vaccination, intranasal administration might be desirable.”

Alan Smith, Ph.D., Archimedes’ Vice President of Research & Development, commented, “We recognize the growing need to improve the efficacy of available antigens and to facilitate mass vaccination by means of innovative approaches such as mucosal administration. As a recognized leader in this field we are excited to be collaborating with ImmuneRegen to apply our world-leading expertise and technology platforms to the intranasal delivery of Homspera.”

About QualityStocks

QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.